Despite several therapeutic advances over the past decade, multiple myeloma (MM)
remains largely incurable, indicating a need for new treatment approaches. Chimeric …

The immune system evolved to distinguish non-self from self to protect the organism. As
cancer is derived from our own cells, immune responses to dysregulated cell growth present …

B-cell maturation antigen (BCMA) is a validated target for chimeric antigen receptor (CAR) T-
cell therapy in multiple myeloma (MM). Despite promising objective response rates, most …

Pemphigus is a group of IgG-mediated autoimmune diseases of stratified squamous
epithelia, such as the skin and oral mucosa, in which acantholysis (the loss of cell adhesion) …

B cell maturation antigen (BCMA) is a novel treatment target for multiple myeloma (MM) due
to its highly selective expression in malignant plasma cells (PCs). Multiple BCMA-targeted …

The approval of the first two monoclonal antibodies targeting CD38 (daratumumab) and
SLAMF7 (elotuzumab) in late 2015 for treating relapsed and refractory multiple myeloma …

B cells play a central role in the immunopathogenesis of glomerulonephritides and
transplant rejection. B cells secrete antibodies that contribute to tissue injury via multiple …

The B cell activating factor (BAFF), or B lymphocyte stimulator (BLyS), is a B cell survival
factor which supports autoreactive B cells and prevents their deletion. BAFF expression is …

Protective responses to microorganisms involve the nonspecific but rapid defence
mechanisms of the innate immune system, followed by the specific but slow defence …

Objective To assess the efficacy/safety of the B lymphocyte stimulator inhibitor belimumab
plus standard therapy compared with placebo plus standard therapy in active systemic lupus …